Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus

被引：0
作者：
Yitong Wang
Bingfeng Xu
Lixia Zhu
Kun Lou
Yingli Chen
Xia Zhao
Qian Wang
Ling Xu
Xiaohui Guo
Linong Ji
Yimin Cui
Yi Fang
机构：
[1] Peking University People’s Hospital,Department of Pharmacy
[2] Peking University,Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical
[3] Xuzhou Medical College,Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy
[4] Anhui Fuyang Pharmaceutical Group Co.,Clinical Medicine Department
[5] Ltd.,Department of Endocrinology
[6] CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co.,Department of Pharmacy
[7] Ltd,Department of Endocrinology
[8] Peking University People’s Hospital,undefined
[9] Peking University First Hospital,undefined
[10] Shanghai University of Chinese Medicine,undefined
[11] Peking University First Hospital,undefined
来源：
Clinical Drug Investigation | 2017年 / 37卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1107 / 1115
页数：8
相关论文
共 50 条
  • [11] Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes
    Bensignor, Megan O.
    Wolf, Jack M.
    Rudser, Kyle D.
    Kelly, Aaron S.
    Arslanian, Silva
    DIABETES OBESITY & METABOLISM, 2022, 24 (07) : 1380 - 1384
  • [12] MEDICATION USE AND TREATMENT PATTERNS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES MELLITUS
    Johnston, S. S.
    Nguyen, H.
    Felber, E.
    Cappell, K.
    Nelson, J.
    Chu, B. C.
    Kalsekar, I
    VALUE IN HEALTH, 2014, 17 (03) : A261 - A262
  • [13] Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study
    Lassen, Mats C. H.
    Johansen, Niklas Dyrby
    Modin, Daniel
    Catarig, Andrei-Mircea
    Vistisen, Bodil Kjeldgaard
    Amadid, Hanan
    Zimmermann, Esther
    Gislason, Gunnar
    Biering-Sorensen, Tor
    DIABETES OBESITY & METABOLISM, 2024, 26 (11) : 5239 - 5250
  • [14] Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes
    Rizzo, Manfredi
    Rizvi, Ali A.
    Sesti, Giorgio
    DIABETES OBESITY & METABOLISM, 2017, 19 (05) : 613 - 614
  • [15] Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
    De Block, Christophe E. M.
    Dirinck, Eveline
    Verhaegen, Ann
    Van Gaal, Luc F.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05) : 788 - 805
  • [16] Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients
    Hopkins, N. D.
    Cuthbertson, D. J.
    Kemp, G. J.
    Pugh, C.
    Green, D. J.
    Cable, N. T.
    Jones, H.
    DIABETES OBESITY & METABOLISM, 2013, 15 (08) : 770 - 773
  • [17] Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
    Babenko, Alina Yu.
    Savitskaya, Daria A.
    Kononova, Yulia A.
    Trofimova, Aleksandra Yu.
    Simanenkova, Anna V.
    Vasilyeva, Elena Yu.
    Shlyakhto, Evgeny V.
    JOURNAL OF DIABETES RESEARCH, 2019, 2019
  • [18] Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States
    Johnston, Stephen S.
    Hiep Nguyen
    Felber, Eugene
    Cappell, Katherine
    Nelson, James K.
    Chu, Bong-Chul
    Kalsekar, Iftekhar
    ADVANCES IN THERAPY, 2014, 31 (11) : 1119 - 1133
  • [19] Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States
    Stephen S. Johnston
    Hiep Nguyen
    Eugene Felber
    Katherine Cappell
    James K. Nelson
    Bong-Chul Chu
    Iftekhar Kalsekar
    Advances in Therapy, 2014, 31 : 1119 - 1133
  • [20] Pharmacokinetics, Pharmacodynamics, and Tolerabili of Single- and Multiple-Dose of Janagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus
    Ding, Yanhua
    DIABETES, 2019, 68
12345